Krystal Biotech Stock Price, News & Analysis

Krystal Biotech (NASDAQ: KRYS) announced that its CEO, Krish S. Krishnan, will participate in two upcoming conferences: H.C. Wainwright's Gene Therapy and Gene Editing Conference on March 30, 2022, at 7:00 a.m. EDT and Guggenheim's 3rd Annual Genomic Medicines and Rare Disease Day on March 31, 2022, from 2:00 to 2:45 p.m. EDT. Webcasts of the presentations will be available, with links to access them provided in the press release. Krystal Biotech focuses on redosable gene therapy for serious diseases, leveraging proprietary technology for potential life-changing treatments.

Krystal Biotech (NASDAQ: KRYS) will showcase late-breaking research on March 26, 2022, at the American Academy of Dermatology Annual Meeting in Boston. The presentation focuses on Phase 3 study results of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa (DEB), a rare and severe skin disease. B-VEC is an investigational topical gene therapy designed to address the genetic causes of DEB by delivering a functional COL7A1 gene. With orphan drug and fast track designations from the FDA, B-VEC aims to provide crucial treatment for DEB patients.

On March 15, 2022, Krystal Biotech (NASDAQ: KRYS) announced a binding term sheet with PeriphaGen to settle trade secret litigation from May 2020. Krystal will acquire biological materials and skin assets from PeriphaGen for $25 million, payable within 10 days after a final settlement agreement, expected within 45 days. Additional milestone payments of $12.5 million will be required upon FDA approval of Krystal's first product and subsequent sales milestones. The settlement includes no admission of liability, and the case is expected to be dismissed within a month.

Krystal Biotech (NASDAQ: KRYS) reported positive news following its GEM-3 pivotal trial for Vyjuvek™, intended to treat dystrophic epidermolysis bullosa. The company plans to file a Biologics License Application (BLA) with the FDA in 1H 2022 and a Marketing Authorization Application (MAA) with the EMA in 2H 2022. Krystal is also set to start a Phase 1 trial for KB407, targeting cystic fibrosis in Australia by mid-2022. The firm maintains a strong financial position, with cash and investments totaling $502.5 million as of December 31, 2021.

Krystal Biotech (NASDAQ: KRYS) announced that CEO Krish S. Krishnan will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference held virtually from March 7-9, 2022. The chat is scheduled for March 7, 2022, from 2:50 to 3:20 p.m. EST. Investors can access the webcast link here. Krystal Biotech specializes in redosable gene therapy, aiming to develop treatments for serious diseases, including rare skin and lung conditions. For further details, visit the official website.

Krystal Biotech (NASDAQ: KRYS) has appointed Jing Marantz as Chief Business Officer and Rand Sutherland to its Board of Directors. Marantz brings over 20 years of experience in biopharmaceuticals, previously serving as Senior VP at Acceleron Pharma. Sutherland, a pulmonologist, has led R&D at Translate Bio and Sanofi. These appointments aim to enhance Krystal's capabilities in advancing their investigational program, VYJUVEK™ for dystrophic epidermolysis bullosa, and other rare diseases. The leadership changes come as the company seeks long-term success in gene therapy innovation.

Krystal Biotech (NASDAQ: KRYS) announced a public offering of 2,666,667 shares at $75.00 each, with gross proceeds expected to reach approximately $200 million. The offering, set to close around December 3, 2021, includes a 30-day option for underwriters to purchase an additional 400,000 shares. Proceeds will fund commercialization efforts for VYJUVEK, advance clinical and preclinical developments for other therapies, and enhance manufacturing capabilities. Goldman Sachs, BofA Securities, Cowen, and William Blair are managing the offering.

Krystal Biotech (NASDAQ: KRYS) has initiated a public offering of $200 million of its common stock, with underwriters granted a 30-day option for an additional $30 million. The proceeds will support commercialization of VYJUVEK for dystrophic epidermolysis bullosa and advance various clinical developments, including therapies for cystic fibrosis and Netherton syndrome. The offering, underpinned by a shelf registration statement filed with the SEC, is subject to market conditions.

Krystal Biotech announced positive results from the pivotal GEM-3 trial of its gene therapy VYJUVEK for treating dystrophic Epidermolysis Bullosa (dystrophic EB). The trial met its primary endpoint, showing a 67% complete wound healing rate at six months compared to 22% for the placebo group. The Biologics License Application (BLA) is set for submission to the FDA in 1H22. VYJUVEK was well tolerated, with no serious adverse events. The success of this trial emphasizes the potential of VYJUVEK to transform treatment for this severe condition.